EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus

Shubha Bhat iD, Ruishen Lyu, Mitali Agarwal, Michelle Becker, Richard Bloomfeld, David H Bruining, Benjamin L Cohen, Marina Ivanov, Jonathan A Leighton, Alyssa P Stewart, Lindsay Trocke, Stacy S Tse und 5 weitere

Inflammatory Bowel Diseases · 03.06.2024 · 30 (6) · 950-959

DOI: 10.1093/ibd/izad143 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 31.08.2023. Verfasst von Shubha Bhat und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Pharmacists, Professional Role. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the complexity of inflammatory bowel disease (IBD) care, utilization of multidisciplinary teams is recommended to optimize outcomes. There is a growing recognition that clinical pharmacists should be an integral part of this care model. We sought to define the roles of IBD clinical pharmacists in the United States.

Methods

A national multidisciplinary expert panel of 12 gastroenterologists and clinical pharmacists practicing in IBD clinics was assembled. We used the RAND/University of California, Los Angeles appropriateness method, with a total of 281 statements generated based on a systematic literature review and expert opinion. Each statement was anonymously rated as appropriate, uncertain, or inappropriate in 2 rounds of voting.

Results

The number of publications evaluating the clinical pharmacists’ roles in IBD is limited, primarily focusing on thiopurine initiation and monitoring, medication adherence, and switching to biosimilars. Medication education; medication initiation and monitoring; therapeutic drug monitoring; biosimilar management; health maintenance review; and transitions of care were deemed by the panel to be appropriate roles for IBD clinical pharmacists. In considering real-world settings, IBD clinical pharmacists should practice clinically under a predefined scope and primarily focus on complex treatments (eg, immunomodulators, biologics, and small molecules). Clinical pharmacists should also be included in practice settings with IBD specialized physicians. Additionally, clinical pharmacists caring for patients with IBD should be residency trained and board certified.

Conclusions

This consensus defines IBD clinical pharmacists’ roles and provides a framework for embedded clinical pharmacists in IBD care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesPharmacistsProfessional RoleHumansPatient Care TeamUnited States

Stichwörter der Autor:innen

Crohn’s diseaseinflammatory bowel diseasemultidisciplinary teamspharmacistsulcerative colitis

Autor:innen und Institutionen

  • Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH, USA.
  • Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, OH, USA.
  • Department of Quantitative Health Science, Cleveland Clinic Foundation, OH, USA.
  • Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
  • Section of Gastroenterology, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Shubha Bhat

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Bhat, S., Lyu, R., Agarwal, M., Becker, M., Bloomfeld, R., Bruining, D. H., Cohen, B. L., Ivanov, M., Leighton, J. A., Stewart, A. P., Trocke, L., Tse, S. S., Ungaro, R. C., Vaughn, B. P., Regueiro, M., Sokn, E., & Rieder, F. (2024). Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus. Inflammatory Bowel Diseases, 30(6), 950-959. https://doi.org/10.1093/ibd/izad143

Vancouver

Bhat S, Lyu R, Agarwal M, Becker M, Bloomfeld R, Bruining DH, et al. Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus. Inflammatory Bowel Diseases. 2024;30(6):950-959. doi:10.1093/ibd/izad143

BibTeX
@article{Bhat2024,
  author = {Bhat, Shubha and Lyu, Ruishen and Agarwal, Mitali and Becker, Michelle and Bloomfeld, Richard and Bruining, David H and Cohen, Benjamin L and Ivanov, Marina and Leighton, Jonathan A and Stewart, Alyssa P and Trocke, Lindsay and Tse, Stacy S and Ungaro, Ryan C and Vaughn, Byron P and Regueiro, Miguel and Sokn, Erick and Rieder, Florian},
  title = {Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA Consensus},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {6},
  pages = {950--959},
  doi = {10.1093/ibd/izad143}
}
Kostenlos starten →